NeuroScientific Biopharmaceuticals Limited (ASX:NSB)

Australia flag Australia · Delayed Price · Currency is AUD
0.110
+0.005 (4.76%)
Apr 29, 2026, 12:49 PM AEST
107.55%
Market Cap 36.58M
Revenue (ttm) 317.91K
Net Income (ttm) -3.18M
Shares Out 332.58M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 62,354
Average Volume 481,653
Open 0.110
Previous Close 0.105
Day's Range 0.110 - 0.110
52-Week Range 0.047 - 0.260
Beta 1.11
RSI 52.93
Earnings Date May 26, 2026

About ASX:NSB

NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Perth, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol NSB
Full Company Profile

Financial Performance

Financial Statements

News

NeuroScientific Biopharmaceuticals Transcript: Investor Update

A new stem cell platform was acquired, shifting focus to Crohn's disease and other high-value indications. Early clinical data is strong, with a special access program underway and phase two trials planned. Manufacturing and advisory partnerships de-risk development and support future expansion.

5 months ago - Transcripts